Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31646

Title:	Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Authors:	Lopez-Vivanco, G Salvador, J Diez, R López, D De Salas-Cansado, M Navarro, B De la Haba-Rodríguez, J View more
Keywords:	Spain Time and motion Trastuzumab View more
Mesh:	Administration, Intravenous Antineoplastic Agents Breast Neoplasms Female Follow-Up Studies Humans Injections, Subcutaneous Middle Aged Prognosis Prospective Studies Receptor, ErbB-2 Spain Trastuzumab Costs and Cost Analysis View more
Issue Date:	Dec-2017
Citation:	Clin Transl Oncol.2017 Dec;(19)12:1454-1461
Abstract:	To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab subcutaneous (SC) formulations in patients with HER2-positive early breast cancer.
PMID:	28577152
URI:	https://hdl.handle.net/20.500.12530/31646
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Getafe > Artículos

Files in This Item:

File	Description	Size	Format
PMC5700215.pdf		878.42 kB	Adobe PDF	View/Open